AFAncy Jenil Franco

Ancy Jenil Franco

*This is an algorithmically generated author record based on publicly available information.

Ancy Jenil Franco has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Optical Coherence Tomography Versus Angiography Alone to Guide PCI for Complex Lesions: A Meta-Analysis of Randomized Controlled Trials

    by Chidubem Ezenna, Mrinal Murali Krishna, Meghna Joseph, Sammudeen Ibrahim, Vinicius Pereira, Ancy Jenil-Franco, Michael G. Nanna, Sripal Bangalore, Andrew M. Goldsweig

    BACKGROUND: Optical coherence tomography (OCT) provides high-resolution intracoronary imaging. However, whether the addition of OCT to angiography to guide percutaneous coronary intervention (PCI) of complex lesions affects clinical outcomes is debated. METHODS: A systematic search for randomized controlled trials was conducted using PubMed, Scopus, and Cochrane databases through September 2024. End points included major adverse cardiovascular events, cardiac death, myocardial infarction, periprocedural myocardial infarction, all-cause mortality, stent thrombosis (definite or probable), and target-vessel revascularization. The random-effects model was used to generate risk ratios (RRs) and 95% CIs. RESULTS: A literature search identified 4 randomized controlled trials including 5603 patients with a median follow-up of 2 years. Compared with PCI guided by angiography alone, OCT-guided PCI was associated with lower major adverse cardiovascular events (RR, 0.68 [95% CI, 0.55–0.84]; P P =0.003), myocardial infarction (RR, 0.75 [95% CI, 0.59–0.96]; P =0.02), all-cause mortality (RR, 0.58 [95% CI, 0.38–0.87]; P =0.009, and stent thrombosis (RR, 0.49 [95% CI, 0.26–0.90]; P =0.02). There was a trend toward lower target-vessel revascularization (RR, 0.67 [95% CI, 0.44–1.03]; P =0.07) and lower periprocedural myocardial infarction (RR, 0.79 [95% CI, 0.59–1.06]; P =0.11) with OCT guidance compared with angiography alone. CONCLUSIONS: The addition of OCT guidance to PCI of complex lesions resulted in better clinical outcomes than angiography guidance alone. Updated guidelines should strengthen recommendations supporting the use of OCT guidance for complex PCI. REGISTRATION: URL: https://www.crd.york.ac.uk/PROSPERO/ ; Unique identifier: CRD42024603847.


  • Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials

    by Mable Pereira, Ancy Jenil Franco, Karthik Chintharala, Ana Carolina Putini Vieira, Ana Carolina Ventura de Santana de Jesus, Paweł Łajczak, Khaled Alhwaishel, Mario Saul Lira Castañeda, Elizabet Taylor Pimenta Weba, Kristian Reich

    Mirikizumab, an interleukin-23 (IL-23) p19 subunit inhibitor, has emerged as a promising treatment for moderate-to-severe plaque psoriasis. Despite its promising results, a comprehensive synthesis of clinical data is essential to assess its overall efficacy and safety profile. We searched PubMed, Embase, and Cochrane for studies assessing mirikizumab in moderate-to-severe psoriasis. A random-effects model using Inverse Variance (IV) computed mean differences (MD) for continuous outcomes and risk ratios (RR) for binary endpoints. Risk Difference (RD) studies were analysed using generic inverse variance (GIV) in Review Manager. Statistical analyses were conducted using R software version 4.2.1, following PRISMA guidelines. This analysis of three RCTs involving 1,649 adult patients over 16-52 weeks demonstrated mirikizumab's significant efficacy in treating psoriasis. At 16 weeks, mirikizumab substantially reduced Body Surface Area (BSA) to < 1% (RR: 34.53, p < 0.001) and improved PASI scores (PASI 100 RR: 25.94, PASI 90 RR: 11.50, PASI 75 RR: 10.47, all p < 0.001). Static Physician's Global Assessment (sPGA) scores of 0/1 were achieved (RR: 12.48, p < 0.001). Quality of life measures also improved significantly, with increases in SF-36 Physical and Mental Component Summaries (MD: 4.02 and 3.53 respectively, p < 0.01) and Dermatology Life Quality Index (DLQI) scores of 0/1 (RD: 0.51, p < 0.00001). Importantly, the safety profile of mirikizumab was comparable to the control, with no significant differences in the overall incidence of adverse effects (RR: 0.97; 95% CI: 0.86-1.10) or in serious adverse effects (RR: 1.61; 95% CI: 0.55-4.73). These results collectively demonstrate the efficacy and safety of mirikizumab in treating psoriasis, with significant improvements across multiple clinical and quality-of-life measures. This meta-analysis demonstrates that mirikizumab significantly reduces psoriasis severity and improves quality of life, with a favourable safety profile. These findings support its use as a valuable treatment option for moderate-to-severe plaque psoriasis. Further research is needed to assess long-term outcomes and comparative effectiveness.


  • Role of GLP1-RA in Optimizing Weight Loss Post-Bariatric Surgery: A Systematic Review and Meta-Analysis

    by Mable Pereira, Shenelle Menezes, Ancy Jenil Franco, Patricia Marcolin, Mark Tomera

    Bariatric surgery is a widely used intervention for significant weight loss, yet some patients face challenges with insufficient weight loss or weight regain post-surgery. To address this issue, adjunctive treatments like glucagon-like peptide-1 receptor agonists (GLP1-RAs) are being explored for their potential to enhance weight loss outcomes. This meta-analysis was conducted to evaluate the effectiveness of GLP1-RAs in improving weight loss after bariatric surgery compared to a placebo. By systematically reviewing and analyzing data from three randomized controlled trials (RCTs) involving 130 patients, we found that GLP1-RA therapy, particularly liraglutide (1.8-3 mg), significantly reduced mean BMI and body weight percentage at six months. Future studies should explore newer GLP1-RAs with weekly dosing and include longer follow-up periods to assess the durability of these outcomes.